HALT Trial Schema

Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease (OPD) in oncogene-addicted lung tumours (HALT)

HALT is a randomised, multi-centre phase II/III trial designed to assess whether the use of SBRT to treat oligo-progressive disease can prolong the period of clinical benefit obtained from targeted therapy. Patients will be randomised to receive SBRT or no SBRT (2:1) with all patients continuing to receive background targeted therapy as per clinical guidelines. HALT incorporates an integrated phase II/III trial design with transition to full phase III dependent on feasibility data obtained during the phase II.



Adapted from the HALT trial protocol – version 7.0, 11th August 2021